Lesinurad is a uric acid 1 transporter inhibitor typically used in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout in patients with inadequate control of uric acid levels with xanthine oxidase inhibitor monotherapy. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia.
- Mechanism
- Curator reviewed
Lesinurad inhibits the activity of uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4). URAT1 is a major transporter enzyme responsible for reuptake of uric acid from the renal tubules; inhibition of URAT1 function thereby increases excretion of uric acid.
- Primary indication
- For use, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.Curator reviewed · 1 structured indication
- Formula / weight
- C17H14BrN3O2S · 404.28 g/mol (avg)
- First approval
- United States, 2016
- Code names
- RDEA-594
Resolves to
FGQFOYHRJSUHMR-UHFFFAOYSA-NSMILESOC(=O)CSC1=NN=C(Br)N1C1=CC=C(C2CC2)C2=C1C=CC=C2What you can answer from here — as of June 15, 2026
Which drugs share a target with Lesinurad, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account